AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL
NEUTRAL
Impact: 3/10
PRESS-RELEASE
Press release: fda
Latest settled — T+20d ⚠ clustered
AAPG ▼ -29.59% at T+20d
NEUTRAL call ✗ call lost -29.59% · α vs SPY -33.79% · entry $26.36 → $18.56
Last close $17.60 (close Jun 12) · -33.23% from $26.36 entry
T+1d
-2.69%
call -2.69% · α -2.04%
$25.65
settled 8w ago
T+5d
-11.34%
call -11.34% · α -12.26%
$23.37
settled 7w ago
T+20d
-29.59%
call -29.59% · α -33.79%
$18.56
settled 4w ago
T+60d
—
call — · α —
—
in 29d
Price Chart
Loading chart...
Executive Summary
Ascentage Pharma announced it will present four preclinical studies at the AACR 2026 Annual Meeting. This is a routine scientific disclosure with no immediate commercial or regulatory implications.
Actionable Insight
Monitor for scientific interest or potential partnerships stemming from the presented data, but expect limited immediate market reaction.
Key Facts
- Ascentage Pharma will present four preclinical studies at AACR 2026 Annual Meeting
- Event dates: April 17–22, 2026 in San Diego, CA
- No new clinical data, regulatory decisions, or financial updates were disclosed
Financial Impact
Minimal near-term financial impact — preclinical data presentations typically do not drive revenue or valuation changes
Risk Factors
- Preclinical results may not translate to clinical success
- No disclosed timelines for clinical development or regulatory filings
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276678 |
17 reports for AAPG
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 14, 2026
today
|
Press Release
| — | awaiting T+5 | — | — |
|
Jun 1, 2026
13d ago
|
6-K
| $19.08 $17.20 | ▼ −9.85% | ▼ −7.10% | $17.60 (−7.76%) |
|
May 28, 2026
17d ago
|
6-K
| $20.01 $17.20 | ▼ −14.04% | ▼ −11.52% | $17.60 (−12.04%) |
|
May 28, 2026
17d ago
|
6-K
| $19.88 $17.87 | ▼ −10.11% | ▼ −10.06% | $17.60 (−11.47%) |
|
May 22, 2026
23d ago
|
6-K
| $21.01 $19.08 | ▼ −9.19% | ▼ −10.86% | $17.60 (−16.23%) |
|
May 22, 2026
24d ago
|
Press Release
| $21.01 $19.08 | ▼ −9.19% | ▼ −10.84% | $17.60 (−16.23%) |
|
May 13, 2026
4w ago
|
6-K
| $21.38 $18.99 | ▼ −11.18% | ▼ −10.02% | $17.60 (−17.68%) |
|
May 12, 2026
4w ago
|
6-K
| $21.16 $18.56 | ▼ −12.29% | ▼ −12.37% | $17.60 (−16.82%) |
|
Apr 22, 2026
7w ago
|
6-K
| $25.13 $22.75 | ▼ −9.47% | ▼ −9.53% | $17.60 (−29.96%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $25.13 $22.75 | ▼ −9.47% | ▼ −9.53% | $17.60 (−29.96%) |
Showing 10 of 17
US Market Status
Market Closed — Opens in 5h 9m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access